LDX lumos diagnostics holdings limited

0.00%

7.3¢

LDX Discussion, page-776

First 776 Last

Share
Profile

Follow
Quest09

1,952 Posts.

181

19/11/24

08:16

Post #: 76666913
Share

Originally posted by Quest09: ↑

Just last month (October), LDX was able to attract a significant amount of institutional funds from at least two professional investment companies (Tenmile and Ryder Capital). The two investment companies together now own 36.9% of LDX. IMO, both of these two investment companies would have done their due diligence checks before agreeing to invest, and IMO they also would have had direct access to quiz and question senior management about LDX's business plans/strategy.

IMO, the fact that two separate institutional investors decided to buy up a large portion of LDX shares can be an indicator of the upside potential available in LDX shares at current prices.

Expand

Originally posted by Quest09: ↑

The US Food and Drug Administration (FDA) is the govt department responsible for granting the LDX CLIA waiver (as per below image).

A successful CLIA waiver will reportedly open up the number of potential sites which can buy FebriDx from 18,000 sites pre-waiver, to 270,000 sites post-waiver. In monetary terms the total available market (TAM) will increase from US $118 million dollars per annum, pre CLIA waiver, to US $1.7 billion per annum, post CLIA waiver (see image below).

So lets see what the FDA has to say about the global problem of antimicrobial resistance. The FDA happens to have a whole webpage addressing this important global problem: https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/antimicrobial-resistance

Some key points from the FDA
The FDA's role and strategic approach to combating antimicrobial resistance is shown below (it seems like the FDA's policy on AMR is completely aligned with LDX's aims with FebriDx):

Expand

Originally posted by Quest09: ↑

WHO Director-General Dr Tedros talks about the URGENT need to tackle antimicrobial resistance (AMR).

Quote: "concrete actions needed to tackle AMR, this includes.........reducing the unnecessary use of antimicrobials in healthcare and agriculture"

This is precisely the problem LDX is working on with FebriDX. With such a massive global focus on this problem, IMO, LDX is very well placed to successfully achieve a PLA code reimbursement on FebriDX (i.e. USA govt covering part/whole of medical clinic's cost of buying and using FebriDx), and then also successfully achieving the FDA CLIA waiver (meaning many more USA clinics are able to freely use the product).

See below links for more details.

IMO, LDX has significant upside potential.

Expand

LDX to be presenting at the Bell Potter Healthcare Conference. LDX's presentation is on Wednesday 20 November.

Good to see LDX working hard to get their name and products in front new and existing potential customers and investors.

LDX Price at posting: 3.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

HotCopper Trends: Final day of quarterlies; Larvotto FID & more

SS1

Sun Silver unveils Maverick Springs assay results

Investor education equals superior returns

LRV

Larvotto hits "go" on Hillgrove Project

I88

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

First 776 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 7.3¢		Change 0.000(0.00%)		Mkt cap ! $54.64M

Open	High	Low	Value	Volume
7.3¢	7.4¢	7.2¢	$395.1K	5.414M

Buyers (Bids)

No.	Vol.	Price($)
1	116619	7.3¢

Sellers (Offers)

Price($)	Vol.	No.
7.4¢	312322	4

View Market Depth

No.	Vol.	Price($)
1	116619	0.073
2	183398	0.072
6	767351	0.071
7	1149000	0.070
7	1375434	0.069

Price($)	Vol.	No.
0.074	312322	4
0.075	1327494	3
0.076	250000	6
0.077	166000	3
0.078	4109600	2

Last trade - 16.10pm 31/07/2025 (20 minute delay)

LDX (ASX) Chart

LDX Discussion, page-776

HotCopper Trends: Final day of quarterlies; Larvotto FID & more

Sun Silver unveils Maverick Springs assay results

Investor education equals superior returns

Larvotto hits "go" on Hillgrove Project

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

LDX Discussion, page-776

Top Stories

HotCopper Trends: Final day of quarterlies; Larvotto FID & more

Sun Silver unveils Maverick Springs assay results

Investor education equals superior returns

Larvotto hits "go" on Hillgrove Project

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News